Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KDR D717V |
| Gene Variant Detail | |
| Relevant Treatment Approaches | VEGFR Inhibitor (Pan) VEGFR2 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR act mut | bladder urothelial carcinoma | predicted - sensitive | Sunitinib | Phase II | Actionable | In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593). | 20142593 |
| KDR act mut | Advanced Solid Tumor | predicted - sensitive | Lucitanib | Phase I | Actionable | In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991). | 25193991 |
| KDR act mut | Advanced Solid Tumor | sensitive | Sorafenib | Preclinical | Actionable | In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655). | 19723655 |
| KDR act mut | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655). | 19723655 |